Pro-anakoinotic therapy with PPARγ agonists may attenuate Wnt signaling as both pathways can be regarded antagonists, thereby concertedly inducing differentiation, enhancing immune response, reducing tumor-associated inflammation, angiogenesis and cell proliferation (99, 100). This evidence concerns the gene PPARG and neoplasm.